Form 4: NeuroPace Director Uri Geiger Acquires 8,745 Stock Options

NeuroPace Inc. Director Uri Geiger has acquired 8,745 stock options with an exercise price of $13.15, vesting over 12 months.

Summary

• Uri Geiger, a Director of NeuroPace Inc. (NPCE), acquired 8,745 stock options on June 6, 2025.
• Each option grants the right to purchase one share of NeuroPace common stock at an exercise price of $13.15.
• The options are set to vest in twelve equal consecutive monthly installments, contingent upon Mr. Geiger's continuous service through each vesting date.
• The acquired stock options have an expiration date of June 5, 2035.
• Following this transaction, Mr. Geiger beneficially owns 8,745 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed as a positive signal, as it aligns the director's financial interests with those of shareholders and indicates confidence in the company's future performance. As a routine compensation event, it's moderately positive rather than a major strategic announcement.

Positives

• The acquisition of stock options by a director aligns their financial interests with those of shareholders, as the options gain value if the company's stock price increases.
• The vesting schedule encourages long-term commitment and continued service from the director.

Risks

• The value of the acquired stock options is directly dependent on the future market performance of NeuroPace Inc.'s common stock; if the stock price does not exceed the exercise price of $13.15, the options may expire worthless.
• The vesting of the options is subject to the reporting person's continuous service, meaning unvested options could be forfeited if the director's service terminates.

Future Outlook

The grant of stock options to a director establishes a long-term incentive structure tied to the company's future stock performance, indicating an alignment of the director's interests with potential future growth and shareholder value creation.

Industry Context

This Form 4 filing represents a routine disclosure of insider equity compensation. In the medical technology and biotechnology sectors, equity incentives such as stock options are commonly used to attract, retain, and motivate key personnel, aligning their financial interests with the company's long-term strategic objectives and shareholder value creation.

Comparison to Industry Standards

• Granting stock options to directors is a widespread practice across publicly traded companies, particularly prevalent in growth-oriented industries like medical technology, to incentivize performance and align interests with shareholders.
• The specified vesting schedule of twelve equal consecutive monthly installments is a common short-to-medium term vesting period for such equity grants, designed to encourage continued service and commitment.
• The exercise price of $13.15, likely set at the market price on the grant date, is typical for incentive stock options, ensuring that the options only gain intrinsic value if the stock price appreciates from the grant date.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholder value creation, as the options become more valuable if the stock price increases, potentially benefiting shareholders.
• Employees: While this specific filing pertains to a director, the use of equity compensation is a common practice across companies to incentivize and retain key personnel, including employees.

Next Steps

• The acquired stock options will vest in twelve equal consecutive monthly installments, subject to Uri Geiger's continuous service.
• The options will become exercisable upon vesting and can be exercised at any time prior to their expiration date of June 5, 2035.

Key Dates

Keywords

NeuroPace Inc., NPCE, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Compensation, Beneficial Ownership